Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Ranchon

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
The Oncologist|September 14, 2024
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital programClaire Lattard, Chloé Herledan, Thibaut Reverdy, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 16, 2016
SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT studyCecile Dollinger, Vérane Schwiertz, Laura Sarfati, et al.
BMC Research Notes|July 5, 2015
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methodsAurélie Bourmaud, Emilie Henin, Fabien Tinquaut, et al.
Annales Pharmaceutiques Francaises|October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer careFlorence Ranchon, Florian Slimano, Maha Ayyoub, et al.
BMC Cancer|November 10, 2011
Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costsFlorence Ranchon, Gilles Salles, Hans-Martin Späth, et al.
Hematological Oncology|October 7, 2017
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?Florence Ranchon, Nicolas Vantard, Emilie Henin, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose IntensityVirginie Larbre, Florence Ranchon, Delphine Maucort-Boulch, et al.
Bulletin Du Cancer|February 27, 2017
[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital]Amandine Baudouin, Emilie Fargier, Ariane Cerruti, et al.
Clinical Therapeutics|March 12, 2014
Administration of anticancer drugs: exposure in hospital nursesCatherine Rioufol, Florence Ranchon, Vérane Schwiertz, et al.
Clinical Interventions in Aging|October 28, 2021
How a Patient Personalised Clinical Pharmacy Programme Can Secure Therapeutic Care in an Orthogeriatric Care Pathway (5P Project)?Marine Barral, Julie Martin, Emmanuelle Carre, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The Oncologist|September 14, 2024
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital programClaire Lattard, Chloé Herledan, Thibaut Reverdy, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 16, 2016
SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT studyCecile Dollinger, Vérane Schwiertz, Laura Sarfati, et al.
BMC Research Notes|July 5, 2015
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methodsAurélie Bourmaud, Emilie Henin, Fabien Tinquaut, et al.
Annales Pharmaceutiques Francaises|October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer careFlorence Ranchon, Florian Slimano, Maha Ayyoub, et al.
BMC Cancer|November 10, 2011
Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costsFlorence Ranchon, Gilles Salles, Hans-Martin Späth, et al.
Hematological Oncology|October 7, 2017
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?Florence Ranchon, Nicolas Vantard, Emilie Henin, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose IntensityVirginie Larbre, Florence Ranchon, Delphine Maucort-Boulch, et al.
Bulletin Du Cancer|February 27, 2017
[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital]Amandine Baudouin, Emilie Fargier, Ariane Cerruti, et al.
Clinical Therapeutics|March 12, 2014
Administration of anticancer drugs: exposure in hospital nursesCatherine Rioufol, Florence Ranchon, Vérane Schwiertz, et al.
Clinical Interventions in Aging|October 28, 2021
How a Patient Personalised Clinical Pharmacy Programme Can Secure Therapeutic Care in an Orthogeriatric Care Pathway (5P Project)?Marine Barral, Julie Martin, Emmanuelle Carre, et al.
Pageof 6